Nanda Ayu Puspita


Abstrak.Kemoprevensimasihmenjadiberdebatan dalam dunia kedokteran. Seperti halnya pencegahan penyakit pada umumnya, kemoprevensi diarahkan untuk menghambat atau memutarbalikkan proses perubahan sel-sel normal menjadi sel-sel ganas (karsinogenesis), dengan memanfaatkan pengetahuan tentang patogenesis kanker, tahapan perkembangan sel kanker, dan penemuan biomarker sebagai penanda kanker. Berbagai uji klinis telah menunjukkan hasil negative maupun hasil positif kemoprevensi, untuk pencegahan kanker payudara, kanker kolon,kanker prostat, dan berbagai macam kanker lainnya. Akan tetapi, sampai saat ini kemoprevensi masih belum bisa diterima secara luas, bukan hanya karena hasil akhirnya yang masih menjadi tanda tanya, namun juga perlu mempertimbangkan keuntungan dan kerugian pemberian kemoprevensi yang notabene akan diberikan pada populasi yang tergolong sehat. Oleh karena itu, tulisan ini akan mengupas kedua sisi kemoprevensi, untuk dapat memberikan gambaran dibalik pro dan kontra pencegahan kanker. (JKS 2016; 2: 112-119)


Kata kunci : Kemoprevensi, kanker.

Abstract. The experts are still debating about cancer chemoprevention. With regards to the prevention of disease, the aim of chemoprevention is to inhibit or reverse the development of cancerous cells from healthy and normal cells (carcinogenesis), by exploiting the advance knowledge of cancer pathogenesis, cancer cell development, and the discovery of cancer biomarkers. A vast number of clinical trials have reported both side of negative and positive results from chemoprevention, for reducing the incidence of breast cancer, colon cancer, prostate cancer, and many more. Nevertheless, chemoprevention is not widely accepted, attributed to the big question of the endpoint to demonstrate the meaningful preventive effect, and the risk-and-benefit of chemoprevention, as the intervention is given to relatively healthy population. Accordingly, this review will expose both aspects of chemoprevention, in order to provide a wider picture behind the controversial of cancer chemoprevention. (JKS 2016; 2: 112-119)

Keywords : Chemoprevention, cancer.


Kemoprevensi; kanker; Chemoprevention; cancer;

Full Text:



Stewart B, Wild CP. World cancer report 2014. World. 2015.

Steward W, Brown K. Cancer chemoprevention: a rapidly evolving field. British journal of cancer. 2013;109(1):1-7.

Wu X, Patterson S, Hawk E. Chemoprevention – History and general principles. Best Practice & Research Clinical Gastroenterology. 2011;25(4–5):445-59.

Gescher A, Pastorino U, Plummer SM, Manson MM. Suppression of tumour development by substances derived from the diet—mechanisms and clinical implications. British Journal of Clinical Pharmacology. 1998;45(1):1-12.

Pitot HC. The molecular biology of carcinogenesis. Cancer. 1993;72(S3):962-70.

Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer research. 1976;36(7 Part 2):2699-702.

Rodenhuis S, van de Wetering ML, Mooi WJ, Evers SG, van Zandwijk N, Bos JL. Mutational activation of the K-ras oncogene. New England Journal of Medicine. 1987;317(15):929-35.

Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. New England Journal of Medicine. 2001;345(4):235-40.

De Flora S, Ferguson LR. Overview of mechanisms of cancer chemopreventive agents. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 2005;591(1):8-15.

Steele VE, Kelloff GJ. Development of cancer chemopreventive drugs based on mechanistic approaches. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 2005;591(1–2):16-23.

Wattenberg LW. Inhibitors of chemical carcinogens. Journal of environmental pathology and toxicology. 1980;3(4 Spec No):35-52.

De Flora S, Ramel C. Mechanisms of inhibitors of mutagenesis and carcinogenesis. Classification and overview. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 1988;202(2):285-306.

Karin M. Nuclear factor-κB in cancer development and progression. Nature. 2006;441(7092):431-6.

Kahl R. Antioxidants and carcinogen metabolism. Trends in Pharmacological Sciences. 1982;3:72-4.

Ip C, Ganther HE. Combination of blocking agents and suppressing agents in cancer prevention. Carcinogenesis. 1991;12(2):365-7.

Pollard M, Luckert P. Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors. Cancer treatment reports. 1979;64(12):1323-7.

Thun MJ, Namboodiri MM, Heath Jr CW. Aspirin use and reduced risk of fatal colon cancer. New England Journal of Medicine. 1991;325(23):1593-6.

Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute. 1998;90(18):1371-88.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prevention Research. 2010;3(6):696-706.

Chang M-H, Chen C-J, Lai M-S, Hsu H-M, Wu T-C, Kong M-S, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. New England Journal of Medicine. 1997;336(26):1855-9.

Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. New England Journal of Medicine. 2002;347(21):1645-51.

Harris R. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology. 2009;17(2):55-67.

Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. New England Journal of Medicine. 2003;349(3):215-24.

Group ACPS. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. Annals of epidemiology. 1994;4(1):1-10.

Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Jama. 2009;301(1):39-51.


  • There are currently no refbacks.

Creative Commons LicenseISSN: 1411-3848E-ISSN: 2579-6372
Copyright© 1987-2017 | ISSN: 1412-1026 | EISSN: 2550-0112 
Jurnal Kedokteran Syiah Kuala is licensed under a Creative Commons Attribution 4.0 International License.


Published by:
Fakultas Kedokteran, Universitas Syiah Kuala
Jl. Tgk. Tanoh Abee, Kopelma Darussalam,
Banda Aceh, 23111, Indonesia.
Phone: +626517551843 

Online Submissions & Guidelines | Editorial Policies | Contact | Statistics | Indexing | Citations